Literature DB >> 23343957

Major histocompatibility complex class I and II expression in idiopathic inflammatory myopathy.

Leena Das1, Peter C Blumbergs, Jim Manavis, Vidya S Limaye.   

Abstract

INTRODUCTION: We sought to study the intensity and pattern of major histocompatibility complex (MHC) I and II expression in muscle from patients with biopsy-proven idiopathic inflammatory myositis (IIM) including the subgroups, polymyositis (PM), dermatomyositis (DM), and inclusion body myositis (IBM).
METHODS: A total of 120 muscle biopsies (61 PM, 14 DM, and 45 IBM) were immunostained for MHC I and II. Staining was graded as follows. 0: no staining, 1+: ≤10% fibers, 2+: 10% to 25%, 3+: 25% to 50%, 4+: 50% to 99%, and 5+ 100%.
RESULTS: All IIM biopsies showed MHC I positivity; 93% showed MHC II positivity. The proportion of patients with MHC II score ≥3+ was higher in IBM than DM or PM. In DM, MHC I expression showed a perifascicular pattern. All IBM biopsies were immunopositive for MHC I and II; 30/45 were scored 5+. DISCUSSION: Immunostaining for MHC I and II is a useful adjunctive test in diagnosis and subclassification of IIM.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23343957     DOI: 10.1097/PAI.0b013e31827d7f16

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  7 in total

1.  Skeletal muscle provides the immunological micro-milieu for specific plasma cells in anti-synthetase syndrome-associated myositis.

Authors:  Corinna Preuße; Barbara Paesler; Christopher Nelke; Derya Cengiz; Thomas Müntefering; Andreas Roos; Damien Amelin; Yves Allenbach; Akinori Uruha; Carsten Dittmayer; Andreas Hentschel; Marc Pawlitzki; Sarah Hoffmann; Sara Timm; Sarah Leonard Louis; Nora F Dengler; Heinz Wiendl; Jan D Lünemann; Albert Sickmann; Baptiste Hervier; Sven G Meuth; Udo Schneider; Anne Schänzer; Sabine Krause; Stylianos Tomaras; Eugen Feist; Rebecca Hasseli; Hans-Hilmar Goebel; Laure Gallay; Nathalie Streichenberger; Olivier Benveniste; Werner Stenzel; Tobias Ruck
Journal:  Acta Neuropathol       Date:  2022-05-25       Impact factor: 15.887

2.  The association between myositis-specific autoantibodies and muscle pathologies in idiopathic inflammatory myopathies.

Authors:  Qiu Xu; Qiu-Xiang Li; Fang-Fang Bi; Hui-Qian Duan; Yue-Bei Luo; Huan Yang
Journal:  Clin Rheumatol       Date:  2020-07-15       Impact factor: 2.980

Review 3.  Diagnosis, pathogenesis and treatment of myositis: recent advances.

Authors:  P-O Carstens; J Schmidt
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

Review 4.  Myositis registries and biorepositories: powerful tools to advance clinical, epidemiologic and pathogenic research.

Authors:  Lisa G Rider; Katalin Dankó; Frederick W Miller
Journal:  Curr Opin Rheumatol       Date:  2014-11       Impact factor: 5.006

5.  Distinct interferon signatures stratify inflammatory and dysimmune myopathies.

Authors:  Muriel Rigolet; Cyrielle Hou; Yasmine Baba Amer; Jessie Aouizerate; Baptiste Periou; Romain K Gherardi; Peggy Lafuste; François Jérôme Authier
Journal:  RMD Open       Date:  2019-02-26

Review 6.  Temporospatial Analysis and New Players in the Immunology of Amyotrophic Lateral Sclerosis.

Authors:  Abhirami K Iyer; Kathryn J Jones; Virginia M Sanders; Chandler L Walker
Journal:  Int J Mol Sci       Date:  2018-02-23       Impact factor: 5.923

Review 7.  Role of Myokines in Myositis Pathogenesis and Their Potential to be New Therapeutic Targets in Idiopathic Inflammatory Myopathies.

Authors:  Vlad Mageriu; Emilia Manole; Alexandra E Bastian; Florica Staniceanu
Journal:  J Immunol Res       Date:  2020-07-24       Impact factor: 4.818

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.